VERA - NASDAQ
Vera Therapeutics, Inc.
$31.27
-7.9%Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
At a Glance
Live SnapshotVera Therapeutics, Inc. Management Team
Mr. Sean P. Grant M.B.A.
Chief Financial Officer
Compensation
$642,000
Mr. Jason S. Carter
Chief Legal Officer
Compensation
$256,700
Dr. Robert M. Brenner M.D.
Chief Medical Officer
Compensation
$828,753
Mr. David L. Johnson M.B.A.
Chief Opearating Officer
Dr. Allen Ebens B.Sc., Ph.D.
Executive Vice President of Research
Compensation
$397,024
Dr. Marshall W. Fordyce M.D.
Founder, President, Chief Executive Officer & Director
Compensation
$1,025,450
Mr. Joseph R. Young M.B.A.
Senior Vice President of Finance & Chief Accounting Officer
Ms. Kelly Rauber
Senior Vice President of Human Resources
Ms. Debra Charlesworth
Vice President of Corporate Communications
Ms. Emma Haywood
Vice President of Marketing
Vera Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $3.77M and sold $4.44M worth of VERA shares, resulting in $673K of net selling activity.
3 Months
0
0.00
28.3K
1.14M
-1.1M
-$1.14M
3-6 Months
5.9K
249.99K
53.5K
2.36M
-2.1M
-$2.11M
6-9 Months
0
0.00
28.9K
943.37K
-943K
-$943K
9-12 Months
166.7K
3.52M
0
0.00
+3.5M
+$3.52M
Top Buyers
Enright Patrick G
Director
$3.77M
Top Sellers
Fordyce Marshall
Director, Officer: President And Ceo
$1.85M
Turner William D.
Officer: Chief Regulatory Officer
$1.45M
Young Joseph R
Officer: Svp, Finance, Chief Acct Offcr
$567K
Grant Sean
Officer: Chief Financial Officer
$208K
Johnson David Lee
Officer: Chief Operating Officer
$108K
Insider Activity Analysis
Net Insider Sentiment
Slightly bearish with $673K net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Buy/Sell Ratio
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Balanced insider activity: Roughly equal buying and selling suggests normal portfolio management rather than strong directional signals. Look to other metrics for clearer investment insights.
SEC Filings
VERA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 09, 2026 | May 21, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 03, 2025 | May 14, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 03, 2024 | May 15, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | March 30, 2023 | May 10, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 14, 2022 | May 24, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.